GPR89B: A Potential Drug Target and Biomarker for NF-kappa-B Activation

Target Name: GPR89B

NCBI ID: G51463

GPR89B

GPR89B: A Potential Drug Target and Biomarker for NF-kappa-B Activation

Non-coding RNA (ncRNA) plays a crucial role in gene regulation and has been implicated in numerous diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. One subgroup of ncRNA, the nuclear factor kappa B (NF-kappa-B), has been identified as a key regulator of inflammation, immune response, and cell survival. Activating transcription factor 3 (ATF3) and its adapter protein GPR89B are involved in the NF-kappa-B signaling pathway. GPR89B has been shown to play a critical role in the regulation of inflammation and may be a drug target or biomarker for various diseases.

GPR89B is a 21-kDa protein that is expressed in various tissues and cells, including immune cells, neurons, and tissues. It is a member of the G protein-coupled receptor (GPCR) family 89, which includes several important signal transduction pathways , including the TGF-灏?, Wnt, and Hedgehog pathways. GPR89B is known for its ability to activate and repress NF-kappa-B signaling, which is a critical pathway involved in inflammation, immune response, and cell survival.

The NF-kappa-B signaling pathway is a complex cascade of interactions that involves the recruitment of various proteins to the nuclear complex, including the transcription factor DNA-binding proteins, such as NF-kappa-B1 and NF-kappa-B6, as well as the adapter proteins, such as GPR89B. GPR89B is one of the adapter proteins that can activate the NF-kappa-B signaling pathway.

Studies have shown that GPR89B plays a critical role in the regulation of inflammation and immune response. GPR89B has been shown to be involved in the regulation of T cell development and activation, as well as the regulation of inflammation. GPR89B has also been shown to be involved in the regulation of cancer cell growth and survival, and may be a potential biomarker for cancer.

In addition to its role in inflammation and immune response, GPR89B has also been shown to play a critical role in the regulation of cell survival. GPR89B has been shown to be involved in the regulation of cell apoptosis, and may be a potential drug target for diseases that are characterized by cellular dysfunction and death, such as neurodegenerative disorders.

GPR89B has also been shown to have potential clinical applications. For example, GPR89B has been shown to be involved in the regulation of the efficacy of anti-inflammatory drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly used to treat inflammatory diseases. Additionally, GPR89B has been shown to be involved in the regulation of the regulation of pain perception, which may be a potential target for analgesics.

In conclusion, GPR89B is a protein that has been shown to play a critical role in the regulation of inflammation, immune response, and cell survival. Its role in these processes makes it a potential drug target or biomarker for various diseases. Further research is needed to fully understand the functions of GPR89B and its potential clinical applications.

Protein Name: G Protein-coupled Receptor 89B

Functions: Voltage dependent anion channel required for acidification and functions of the Golgi apparatus that may function in counter-ion conductance (PubMed:12761501, PubMed:18794847). Plays a role in lymphocyte development, probably by acting as a RABL3 effector in hematopoietic cells (By similarity)

The "GPR89B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR89B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets